Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

Sanam Loghavi, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, Meenakshi Mehrotra, L. Jeffrey Medeiros, Raja Luthra, Pei Lin, Yang Huh, Hagop M. Kantarjian, Jorge E. Cortes, Srdan Verstovsek, Keyur P. Patel

Research output: Contribution to journalLetter

15 Scopus citations
Original languageEnglish (US)
Pages (from-to)3360-3363
Number of pages4
JournalBlood
Volume125
Issue number21
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Loghavi, S., Pemmaraju, N., Kanagal-Shamanna, R., Mehrotra, M., Medeiros, L. J., Luthra, R., Lin, P., Huh, Y., Kantarjian, H. M., Cortes, J. E., Verstovsek, S., & Patel, K. P. (2015). Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood, 125(21), 3360-3363. https://doi.org/10.1182/blood-2015-03-632893